Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole (1 - 3 mg/Day) as Monotherapy or as Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary) ; Sertraline
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 03 Jan 2019 Status changed from active, no longer recruiting to completed.
- 30 Nov 2018 Results presented in the Lundbeck A/S media release.
- 30 Nov 2018 According to a Lundbeck A/S media release, the company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the results of this trial and to evaluate continuation of the program.